ATE213950T1 - Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen - Google Patents

Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen

Info

Publication number
ATE213950T1
ATE213950T1 AT94202534T AT94202534T ATE213950T1 AT E213950 T1 ATE213950 T1 AT E213950T1 AT 94202534 T AT94202534 T AT 94202534T AT 94202534 T AT94202534 T AT 94202534T AT E213950 T1 ATE213950 T1 AT E213950T1
Authority
AT
Austria
Prior art keywords
stimulating factor
producing
cytomegalovirus infections
against cytomegalovirus
recombinant colony
Prior art date
Application number
AT94202534T
Other languages
English (en)
Inventor
Peter Ralph
Kong Teck Chong
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/099,872 external-priority patent/US5104650A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE213950T1 publication Critical patent/ATE213950T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94202534T 1987-09-22 1988-09-16 Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen ATE213950T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/099,872 US5104650A (en) 1985-02-05 1987-09-22 Uses of recombinant colony stimulating factor-1
US24325388A 1988-09-14 1988-09-14

Publications (1)

Publication Number Publication Date
ATE213950T1 true ATE213950T1 (de) 2002-03-15

Family

ID=26796577

Family Applications (2)

Application Number Title Priority Date Filing Date
AT94202534T ATE213950T1 (de) 1987-09-22 1988-09-16 Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen
AT88908821T ATE121944T1 (de) 1987-09-22 1988-09-16 Verwendungen von rekombinantem koloniestimulierendem faktor-1.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT88908821T ATE121944T1 (de) 1987-09-22 1988-09-16 Verwendungen von rekombinantem koloniestimulierendem faktor-1.

Country Status (7)

Country Link
EP (3) EP0643972B1 (de)
JP (2) JP2831012B2 (de)
AT (2) ATE213950T1 (de)
AU (1) AU625807B2 (de)
CA (1) CA1322158C (de)
DE (2) DE3853721T2 (de)
WO (1) WO1989002746A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
EP0643972B1 (de) * 1987-09-22 2002-03-06 Chiron Corporation Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
AU5355790A (en) * 1989-04-19 1990-11-16 Cetus Corporation Multifunctional m-csf proteins and genes encoding therefor
WO1991008754A1 (fr) * 1989-12-13 1991-06-27 Otsuka Pharmaceutical Co., Ltd. Application medicinale de m-csf
US5714140A (en) * 1989-12-13 1998-02-03 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting the production of bioactive IL-1 by administering M-CSF
ATE190497T1 (de) * 1990-08-23 2000-04-15 Chiron Corp Verwendung des rekombinanten koloniestimulierenden faktors-1
US5087453A (en) * 1990-11-01 1992-02-11 Otsuka Pharmaceutical Co., Ltd. Method for the treatment of bacterial caused weight loss and/or hypoglycemia
EP0973904A1 (de) * 1997-03-04 2000-01-26 Chiron Corporation Zusammensetzungen und Verwendungen von M-CSF-alpha
US7618621B2 (en) 2002-01-14 2009-11-17 The Board Of Trustees Of The University Of Illinois Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof
RU2256471C1 (ru) * 2003-11-13 2005-07-20 Мориков Дмитрий Дмитриевич Способ лечения лейкопении при химиолучевой терапии
US8202223B2 (en) 2008-09-19 2012-06-19 Medtronic, Inc. Method and apparatus for determining respiratory effort in a medical device
EP3395356B1 (de) * 2011-02-18 2021-05-19 Stemdr Inc. Zusammensetzung mit einem induktor der sirt1-expression zur vorbeugung oder behandlung von sepsis oder septischen schocks
JP7791642B2 (ja) 2017-05-24 2025-12-24 ノバルティス アーゲー 抗体－サイトカイングラフト化タンパク質及び癌の治療における使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230697A (en) * 1978-07-03 1980-10-28 Morinaga Milk Industry Co. Ltd. Virus-inactivated HGI-glycoprotein capable of stimulating proliferation and differentiation of human granulocyte, process for preparing same and leukopenia curative containing same
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
JP2512453B2 (ja) * 1985-02-05 1996-07-03 シ−タス コ−ポレ−シヨン 天然のコロニ−促進因子―１の精製
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
JP2561255B2 (ja) * 1985-02-05 1996-12-04 シタス コ−ポレイシヨン 組換コロニ−刺激因子▲下−▼１
ATE79761T1 (de) * 1985-11-27 1992-09-15 Genetics Inst Behandlung einer krankheit vom aids-typ.
JPS62169799A (ja) * 1986-01-22 1987-07-25 Otsuka Pharmaceut Co Ltd マクロフア−ジ分化増殖促進物質
HU212277B (en) * 1986-05-06 1996-04-29 Genetics Inst Process for producing m-csf
JP2583770B2 (ja) * 1986-09-17 1997-02-19 大塚製薬株式会社 遺伝子
AU8313187A (en) * 1986-12-31 1988-07-07 Cetus Corporation Pharmaceutical composition of colony stimulating factor-i and granulocyte colony stimulating factor
DE3875859T2 (de) * 1987-03-02 1993-05-13 Genetics Inst Zubereitungen zur verbesserung der adcc-therapien.
EP0643972B1 (de) * 1987-09-22 2002-03-06 Chiron Corporation Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
DK54589A (da) * 1988-02-08 1989-08-09 Otsuka Pharma Co Ltd Humane kolonistmulerende faktorer

Also Published As

Publication number Publication date
EP0643972B1 (de) 2002-03-06
DE3856516D1 (de) 2002-04-11
JPH09328435A (ja) 1997-12-22
EP0379522B1 (de) 1995-05-03
EP0643972A3 (de) 1995-05-17
EP0379522A1 (de) 1990-08-01
DE3853721D1 (de) 1995-06-08
CA1322158C (en) 1993-09-14
DE3853721T2 (de) 1995-10-19
DE3856516T2 (de) 2002-10-10
AU625807B2 (en) 1992-07-16
EP1175911A3 (de) 2003-01-15
ATE121944T1 (de) 1995-05-15
WO1989002746A1 (en) 1989-04-06
JPH03501382A (ja) 1991-03-28
EP0643972A2 (de) 1995-03-22
JP2846629B2 (ja) 1999-01-13
EP1175911A2 (de) 2002-01-30
AU2527888A (en) 1989-04-18
JP2831012B2 (ja) 1998-12-02

Similar Documents

Publication Publication Date Title
ATE213950T1 (de) Verwendung von rekombinantem koloniestimulierendem faktor-1 zur herstellung eines medikaments gegen cytomegalovirusinfektionen
DE3876052D1 (de) Medizinische verwendung.
ATE126235T1 (de) Modifizierter humaner g-csf.
DE3751922D1 (de) Herstellung und Verwendung von IL-6
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
ATE109979T1 (de) Verwendung von guanidinderivaten zur herstellung eines arzneimittels mit npy-antagonistischer wirkung.
DE68905203D1 (de) Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
ATE79545T1 (de) Verwendung vom ''cartilage-inducing faktor b(cif- b)'' zur herstellung eines arzneimittels gegen das wachstum von tumoren.
DK399288A (da) Dobbeltstrenget rna-korrektion af abnormiteter i cirkulerende immunkomplekser og monocytfunktion
ATE167701T1 (de) Human-nervenwachstumsfaktor
ATE191849T1 (de) Verwendung von (s)-(-)-alpha-ethyl-2-oxo-1- pyrrolidinacetamid zur herstellung eines medikaments zur behandlung von angst
ATE107168T1 (de) Verwendung von gepiron zur herstellung eines pharmazeutischen präparats zur behandlung atypischer depression.
DE69004794D1 (de) Verwendung eines Polypeptids mit Interleukin 2-Aktivität zur Herstellung einer zur Behandlung von einfachen Pleurageschwüren bestimmten pharmazeutischen Zusammensetzung.
DE68909267D1 (de) Medikament zur Behandlung von fibrotischer Störung und antifibrotische Verbindung.
DK12990A (da) Human granulocyt-makrofag-kolonistimulerende faktor og muteiner heraf
DE69021257D1 (de) Verwendung von IFN-gamma zur Herstellung einer pharmazeutischen Zusammensetzung für die Behandlung von ATL.
DE69226525D1 (de) Verwendung von aus blutplättchen gewonnenem wachstumsfaktor zur herstellung eines medikaments zur behandlung von gastrointestinaler geschwüre
ATE178651T1 (de) Expression von osteogenem faktor op-1 in mit rekombinantem baculovirus infizierten spodoptera frugiperda-zellen
HUT63441A (en) Megakariocyte colony stimultating factor protein
ATE164077T1 (de) Die verwendung von interleukin-6 zur herstellung einer pharmazeutischen zusammensetzung zur behandlung von lymphocytic leukemia und b-zell lymphoma.
DE68919593D1 (de) Verwendung von Zofenopril zur Herstellung von Medikamenten gegen rheumatoide Arthritis.
TW217382B (de)
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties